Fondaparinux: A synthetic selective factor-Xa inhibitor

Heart Disease

Volumn 5, Issue 4, 2003, Pages 295-302

  Wong, Nina N ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Antithrombotics; Deep vein thrombosis; Factor Xa inhibitor; Fondaparinux; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DIGOXIN; ENOXAPARIN; FONDAPARINUX; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; BACTERIAL ENDOCARDITIS; BLEEDING; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CORONARY ARTERY DILATATION; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; EPIDURAL HEMATOMA; HEART MUSCLE ISCHEMIA; HIP FRACTURE; HUMAN; KIDNEY DISEASE; KNEE ARTHROPLASTY; META ANALYSIS; MULTICENTER STUDY; OUTCOMES RESEARCH; PARAMETER; PHASE 2 CLINICAL TRIAL; PROPHYLAXIS; PROTHROMBIN TIME; RANDOMIZATION; REVIEW; SPINAL CORD HEMORRHAGE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; UNSTABLE ANGINA PECTORIS;

ANTITHROMBIN III; ARTHROPLASTY; HUMANS; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOSIS;

EID: 0043123406     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hdx.0000080719.75044.b0     Document Type: Review

References (29)

1. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162:1182-1189.
2. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119:132S-175S.
3. Samama MM. Applying risk assessment models in general surgery: effective risk stratification. Blood Coagul Fibrinolysis. 1999;10(suppl 2):S79-84.
4. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
5. Bounameaux H, Perneger T. Fondapariunx: a new synthetic pentasaccharide for thrombosis prevention. Lancet. 2002;359:1710-1711.
6. Olson ST, Björk I, Sheffer R, et al. Tole of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. J Biol Chem. 1992;267:12528-12538.
7. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG, for the European Pentasccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: a randomized double blind comparison. Lancet. 2002;359:1715-1720.
8. Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost. 1996;76:5-8.
9. Fondapariunux (Arixtra) package insert. West Orange, New Jersey: Organon Sanofi-Synthelabo. December 2001.
10. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002;41(suppl 2):1-9.
11. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost. 1995;74:1468-1473.
12. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345: 1298-1304.
13. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Pentathlon 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip replacement surgery: a randomized double blind trial. Lancet. 2002;359:1721-1726.
14. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305-1310.
15. Vormfelde SV. Enoxaparin or fondaparinux for thrombosis prevention after orthopedic surgery (letter). Lancet. 2002;360:1701.
16. Bounameaux H, Perneger T. Enoxaparin or fondaparinux for thrombosis prevention after orthopedic surgery (letter). Lancet. 2002;360:1702.
17. Diuguid DL. Choosing a parenteral anticoagulant agent. N Engl J Med. 2001;345:1340-1342.
18. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor Xa inhibitor (ORG31540/SR90107A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study. Eur Heart J. 2001;22: 1716-1724.
19. Sorelle R. Cardiovascular news. Circulation. 2001;104:e9053-9055.
20. Vuillemenot A, Schlele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb Haemost. 1999;81:214-220.
21. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a Phase II evaluation. Circulation. 2000; 102:2726-2731.
22. Amiral J, Lormeau JC, Vissac AM, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 1997;8:114-117.
23. Faaij RA, Burggraaf J, Schoemaker RC, et al. The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin. Clin Pharmacokinet. 2002;41(suppl 2):27-29.
24. Donat F, Ollier C, Santoni A, Duvauchelle T. Safety and pharmacokinetics of co-administration of the first synthetic factor Xa inhibitor and aspirin in human volunteers [abst]. Blood. 2000;96:54a.
25. Ollier C, Faaij RA, Santoni A, et al. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet. 2002;41(suppl 2):31-37.
26. Mant T, Fournie P, Ollier C, et al. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet. 2002;41(suppl 2):39-45.
27. Bijsterveld NR, Moons AH, Boekholdt SM. et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106:2550-2554.
28. Linkins LA, Julian JA, Rischke J, et al. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res. 2002;107:241-244.
29. Lassen MR, Turpie AGG. Fondaparinux versus enoxaparin for prevention of venous thromboembolism. Lancet. 2002;360:1603-1605.